Retatrutide (LY3437943): Research Profile
Also: LY3437943, LY-3437943, GLP-1/GIP/glucagon triple agonist, GGG tri-agonist, triagonist
This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more
Retatrutide (developer designation LY3437943) is an investigational synthetic peptide described in the research literature as a single molecule designed to act as an agonist at three receptors: the GLP-1, GIP, and glucagon receptors. It has been examined in preclinical (cell and animal) models and in early-to-mid-stage human clinical research concerning metabolic and energy-balance signaling pathways. It is not an approved product, and the available evidence is preliminary and should be interpreted cautiously given study-design and translation limitations. This profile is provided for research and educational purposes only and makes no claims regarding safety, efficacy, or any health outcome.
Mechanism as described in the literature
Retatrutide (research designation LY3437943) is characterized in the scientific literature as a synthetic peptide engineered to act at three receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This combined or "triagonist" receptor activity is what distinguishes it, in the literature, from the single- and dual-incretin receptor agonists discussed elsewhere.
Mechanistic and preclinical reports describe these receptor pathways in the context of insulin and glucagon signaling and energy- and lipid-handling processes studied in cell and animal models. Because each receptor is reported to contribute differently, the net pharmacology is an area of active investigation. The translation of mechanistic and early human findings to broader conclusions remains uncertain and requires careful interpretation; nothing here should be read as describing an effect, benefit, or outcome in humans.
Research areas
- Incretin and glucagon receptor pharmacology (in vitro / mechanistic)
- Glucose homeostasis and insulin signaling in animal models
- Energy-balance and food-intake signaling pathways in preclinical research
- Hepatic lipid-metabolism processes in preclinical models
- Comparative pharmacology of mono-, dual-, and triple-receptor agonists
Documentation notes
References
Frequently asked questions
What is retatrutide?+
It is an investigational synthetic peptide (research designation LY3437943) described in the literature as a single molecule that acts as an agonist at the GLP-1, GIP, and glucagon receptors. It is studied in preclinical and early clinical research and is not an approved product.
Is retatrutide proven, safe, or effective?+
No such conclusions can be drawn from this profile. It is an investigational compound; the available evidence is preliminary, and this material makes no claims about safety, efficacy, or any health outcome.
What does the research literature focus on?+
Published and preclinical reports primarily examine its receptor pharmacology and the signaling pathways involved, studied in cell, animal, and early human research. These remain areas of active investigation that require careful interpretation, and findings may not translate beyond the studied models.